News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
David Planchard: Genetic Biomarker Study of Sunvozertinib for Clinical Prognosis and Prediction in NSCLC
David Planchard/oncostream.com
May 12, 2025, 14:51

David Planchard: Genetic Biomarker Study of Sunvozertinib for Clinical Prognosis and Prediction in NSCLC

David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:

“Important study of biomarkers of the potent EGFR exon20ins inhibitor sunvozertinib: ctDNA and resistance mechanism identification to help us in our therapeutic strategies.”

Title: Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.

Authors: Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, Ludovic Doucet, Jianying Zhou, Yongsheng Wang, David Planchard, Yun Fan, Bo Jin, Zhigang Han, Laurent Greillier, Julien Mazieres, Meili Sun, Ying Hu, Xia Song, Cuimin Ding, Lin Wu, Kejing Tang, Li Liang, Yu Yao, Mengzhao Wang

Read The Full Article at Cell Reports Medicine.

David Planchard: Genetic Biomarker Study of Sunvozertinib for Clinical Prognosis and Prediction in NSCLC

More posts featuring David Planchard on OncoDaily.

Bo Jin cancer Cuimin Ding David Planchard James Chih-Hsin Yang Jianying Zhou Julien Mazières Kejing Tang Laurent Greillier Li Liang Lin Wu Ludovic Doucet Meili Sun Mengzhao Wang OncoDaily Oncology Xia Song Yan Xu Yanqiu Zhao Ying Hu Yongsheng Wang Yu Yao Yun Fan Zhigang Han
Special Coverage
Blog
Jun 23, 2025, 07:14
Roberto Martin: An Especially Intense but Beautiful Three Weeks from ASCO to START Barcelona
Blog
Jun 23, 2025, 07:10
Giannis Mountzios Reflects on DeLLphi-304 Trial Impact on Recurrent SCLC
Dialogues
Jun 23, 2025, 07:07
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
Blog
Jun 23, 2025, 07:01
Ibrahim Halil Sahin: I received the David Roodman Excellence in Mentoring Award
Insight
Jun 23, 2025, 06:59
Jason Westin: Mosun-Pola Is Superior to Chemotherapy for Patients with Aggressive Lymphoma
Blog
Jun 23, 2025, 06:51
Sakditad Saowapa: Excited to Share Our Work at ISTH 2025
Blog
Jun 23, 2025, 06:46
Charles Roberts Highlights Father–Son Scientists Advancing Research at St. Jude
Science
Jun 23, 2025, 06:44
The First AI-Powered Platinum Drug Candidate That Defeats Cisplatin Resistance - The Babak Lab
Blog
Jun 23, 2025, 06:38
Shivani Modi: Elderly Woman’s Battle with Post-Transfusion Purpura and Alveolar Haemorrhage
Blog
Jun 23, 2025, 06:04
Vivek Subbiah: Reflecting on a Successful ASCO and the Bright Future of Cancer Treatment
Insight
Jun 23, 2025, 05:54
Marc Oliva Highlights Landmark Study for LA-HNSCC Published in NEJM
Blog
Jun 23, 2025, 05:42
Emad Shash: Calling All Oncology and Allied-Health Professionals